Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma
Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma
Background: Oesophageal adenocarcinoma (OAC) is increasingly common in the west, and survival remains poor at 10-15 % at 5 years. Immune responses are increasingly implicated as a determining factor of tumour progression. The ability of lymphocytes to recognise tumour antigens provides a mechanism for a host immune attack against cancer providing a potential treatment strategy.
Materials and methods: Tumour infiltrating lymphocytes (TILs: CD3+, CD4+, CD8+ and FOXp3+) were assessed by immunohistochemistry using tissue microarrays in a contemporary and homogeneous cohort of OAC patients (n = 128) undergoing curative treatment.
Results: Multivariate analysis identified three independent prognostic factors for improved cancer-specific survival (CSS): increased CD8+ TILs (p = 0.003), completeness of resection (p < 0.0001) and lower pathological N stage (p < 0.0001). Independent prognostic factors for favourable disease-free survival included surgery-only treatment (p = 0.015), completeness of resection (p = 0.001), increased CD8+ TILs (p < 0.0001) and reduced pathological N stage (p < 0.0001). Higher levels of TILs in the pathological specimen were associated with significant pathological response to neoadjuvant chemotherapy (NAC). On multivariate analysis increased levels of CD4+ (p = 0.017) and CD8+ TILs (p = 0.005) were associated with significant local tumour regression and lymph node downstaging, respectively.
Discussion: Our results establish an association of TILs and survival in OAC, as seen in other solid tumours, and identify particular TIL subsets that are present at higher levels in patients who responded to NAC compared to non-responders. These findings highlight potential therapeutic strategies in EAC based on utilising the host immunological response and highlight the immune responses biomarker potential.
651-662
Noble, Fergus
4f14574c-28f2-4e04-bd95-f53c7649e1fa
Mellows, Toby
92bddc4c-d95e-4348-aec0-da4fd6474190
McCormick Matthews, Leo H.
1fca3186-c70a-410c-8a0c-5ad188f2fb34
Bateman, Adrian
35f5fef8-6358-42ff-b3c1-2ff226b4dc43
Harris, Scott
19ea097b-df15-4f0f-be19-8ac42c190028
Underwood, Tim
8e81bf60-edd2-4b0e-8324-3068c95ea1c6
Byrne, James P.
e3d5b8fe-1b69-441c-a173-e084fe5372a6
Bailey, Ian S.
073dd11d-7b7d-43e0-a412-be0b2feb0620
Sharland, Donna M.
345bbc22-3208-47b2-a2f5-5b9fd94ffd2e
Kelly, Jamie J.
0110cc21-7ece-4ab1-92ae-46b3e7d5c650
Primrose, John N.
d85f3b28-24c6-475f-955b-ec457a3f9185
Sahota, Surinder S.
66c1457f-cba2-4c49-9c8c-fcee0748b6b8
Bateman, Andrew R.
a851558d-8b9b-4020-b148-a239c2b26815
Thomas, Gareth J
2ff54aa9-a766-416b-91ee-cf1c5be74106
Ottensmeier, Christian H.
42b8a398-baac-4843-a3d6-056225675797
June 2016
Noble, Fergus
4f14574c-28f2-4e04-bd95-f53c7649e1fa
Mellows, Toby
92bddc4c-d95e-4348-aec0-da4fd6474190
McCormick Matthews, Leo H.
1fca3186-c70a-410c-8a0c-5ad188f2fb34
Bateman, Adrian
35f5fef8-6358-42ff-b3c1-2ff226b4dc43
Harris, Scott
19ea097b-df15-4f0f-be19-8ac42c190028
Underwood, Tim
8e81bf60-edd2-4b0e-8324-3068c95ea1c6
Byrne, James P.
e3d5b8fe-1b69-441c-a173-e084fe5372a6
Bailey, Ian S.
073dd11d-7b7d-43e0-a412-be0b2feb0620
Sharland, Donna M.
345bbc22-3208-47b2-a2f5-5b9fd94ffd2e
Kelly, Jamie J.
0110cc21-7ece-4ab1-92ae-46b3e7d5c650
Primrose, John N.
d85f3b28-24c6-475f-955b-ec457a3f9185
Sahota, Surinder S.
66c1457f-cba2-4c49-9c8c-fcee0748b6b8
Bateman, Andrew R.
a851558d-8b9b-4020-b148-a239c2b26815
Thomas, Gareth J
2ff54aa9-a766-416b-91ee-cf1c5be74106
Ottensmeier, Christian H.
42b8a398-baac-4843-a3d6-056225675797
Noble, Fergus, Mellows, Toby, McCormick Matthews, Leo H., Bateman, Adrian, Harris, Scott, Underwood, Tim, Byrne, James P., Bailey, Ian S., Sharland, Donna M., Kelly, Jamie J., Primrose, John N., Sahota, Surinder S., Bateman, Andrew R., Thomas, Gareth J and Ottensmeier, Christian H.
(2016)
Tumour infiltrating lymphocytes correlate with improved survival in patients with oesophageal adenocarcinoma.
Cancer Immunology Immunotherapy, 65 (6), .
(doi:10.1007/s00262-016-1826-5).
(PMID:27020682)
Abstract
Background: Oesophageal adenocarcinoma (OAC) is increasingly common in the west, and survival remains poor at 10-15 % at 5 years. Immune responses are increasingly implicated as a determining factor of tumour progression. The ability of lymphocytes to recognise tumour antigens provides a mechanism for a host immune attack against cancer providing a potential treatment strategy.
Materials and methods: Tumour infiltrating lymphocytes (TILs: CD3+, CD4+, CD8+ and FOXp3+) were assessed by immunohistochemistry using tissue microarrays in a contemporary and homogeneous cohort of OAC patients (n = 128) undergoing curative treatment.
Results: Multivariate analysis identified three independent prognostic factors for improved cancer-specific survival (CSS): increased CD8+ TILs (p = 0.003), completeness of resection (p < 0.0001) and lower pathological N stage (p < 0.0001). Independent prognostic factors for favourable disease-free survival included surgery-only treatment (p = 0.015), completeness of resection (p = 0.001), increased CD8+ TILs (p < 0.0001) and reduced pathological N stage (p < 0.0001). Higher levels of TILs in the pathological specimen were associated with significant pathological response to neoadjuvant chemotherapy (NAC). On multivariate analysis increased levels of CD4+ (p = 0.017) and CD8+ TILs (p = 0.005) were associated with significant local tumour regression and lymph node downstaging, respectively.
Discussion: Our results establish an association of TILs and survival in OAC, as seen in other solid tumours, and identify particular TIL subsets that are present at higher levels in patients who responded to NAC compared to non-responders. These findings highlight potential therapeutic strategies in EAC based on utilising the host immunological response and highlight the immune responses biomarker potential.
This record has no associated files available for download.
More information
Accepted/In Press date: 8 March 2016
e-pub ahead of print date: 28 March 2016
Published date: June 2016
Organisations:
Cancer Sciences
Identifiers
Local EPrints ID: 395572
URI: http://eprints.soton.ac.uk/id/eprint/395572
ISSN: 0340-7004
PURE UUID: 6ab1f6c0-597b-42e6-bb39-fc0300270c20
Catalogue record
Date deposited: 01 Jun 2016 13:42
Last modified: 15 Mar 2024 03:17
Export record
Altmetrics
Contributors
Author:
Fergus Noble
Author:
Toby Mellows
Author:
Leo H. McCormick Matthews
Author:
Adrian Bateman
Author:
James P. Byrne
Author:
Ian S. Bailey
Author:
Donna M. Sharland
Author:
Jamie J. Kelly
Author:
Surinder S. Sahota
Author:
Andrew R. Bateman
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics